DPP4 and cardiovascular disorder: Is the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) vs dipeptidyl peptidase 4 inhibitors (DPP4is) associated with reduced total cardiovascular disease (CVD) risks for patients with type 2 diabetes (T2D)?